Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel plus carboplatin as first-line adjuvant chemotherapy after incomplete debulking in advanced ovarian cancer
ChiCTR2200057542Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Mar 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in Ovarian Epithelial Adenocarcinoma, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: 2-year progression-free survival rate. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
paclitaxelcarboplatin
03
Conditions
Ovarian Epithelial Adenocarcinomafallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2200057542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057542.